Actelion ($ATLN) CEO Jean-Paul Clozel has been clear about the importance of macitentan for the Swiss biotech’s future in the blockbuster market for pulmonary arterial hypertension (PAH) drugs. So investors appeared to take notice when it was repo…
Archive for the ‘Actelion’ Category
Actelion hunts for answers about 120 deaths in key drug trial
February 14th, 2012 
Ryan McBride 
Posted in Actelion, Blog, Companies, Diagnostics, Funding, macitentan, Medical Devices, Medical Supply, Pharmaceuticals, pulmonary arterial hypertension, Startups, Tracleer, Universities, Videos 
Tags: biotech food social media 
Comments OffActelion hunts for answers about 120 deaths in key drug trial
February 14th, 2012 Ryan McBride Actelion ($ATLN) CEO Jean-Paul Clozel has been clear about the importance of macitentan for the Swiss biotech’s future in the blockbuster market for pulmonary arterial hypertension (PAH) drugs. So investors appeared to take notice when it was repo…
Posted in Actelion, Blog, Companies, Diagnostics, Funding, macitentan, Medical Devices, Medical Supply, Pharmaceuticals, pulmonary arterial hypertension, Startups, Tracleer, Universities, Videos Tags: biotech food social media Comments OffAnalysts give Actelion’s key lung drug 63% odds of success
January 31st, 2012 Ryan McBride Swiss biotech Actelion ($ATLN) could use a win for its experimental lung drug. In need for a new product to follow its big hit Tracleer, the company’s big moment for its lung disease treatment macitentan is likely to come in the second quarter when lat…
Posted in Actelion, Amgen, Blog, Clinical Trial Results, Companies, Diagnostics, Funding, Medical Devices, Medical Supply, Pharmaceuticals, pulmonary arterial hypertension, Startups, Tracleer, Universities, Videos Tags: biotech food social media Comments OffActelion braces for looming pivotal data on blockbuster macitentan program
January 11th, 2012 John Carroll Actelion’s ($ATLN) approach to the year ahead might best be described as hoping for the best while preparing for the worst. Crucial late-stage data on macitentan is due to read out in the second quarter of this year, and CEO Jean-Paul Clozel told a Blo…
Posted in Actelion, Blog, Companies, Diagnostics, Funding, macitentan, Medical Devices, Medical Supply, Pharmaceuticals, pulmonary arterial hypertension, Startups, Tracleer, Universities, Videos Tags: biotech food social media Comments Off